1201 North Shore Blvd. Burlington, Ontario, Canada L7S 1Z5.
Saudi Pharm J. 2012 Jul;20(3):211-5. doi: 10.1016/j.jsps.2012.01.006. Epub 2012 Jan 28.
Inadequate access to useful scientifically accurate patient information is a major cause of the inappropriate use of drugs resulting in serious personal injury and related costs to the health care system. The definition of useful scientifically accurate patient information for prescription drugs was accepted by the US Secretary of the Department of Health and Human Services in 1996 as that derived from or consistent with the US FDA approved professional product label for a drug. Previous quality content studies found that English language patient drug information leaflets distributed by US pharmacies failed to meet minimum criteria defining useful and scientifically accurate information.
Evaluation forms containing the explicit elements that define useful scientifically accurate information for three drugs with known serious adverse drug reactions were created based on the current US FDA approved professional product labels. The Arabic language patient drug information leaflets for celecoxib, paroxetine, and lamotrigine were obtained locally and evaluated using a methodology similar to that used in previous quality content patient drug information studies in the US. The Arabic leaflets failed to meet the definition of useful scientifically accurate information. The celecoxib leaflet contained 30% of the required information and the paroxetine and lamotrigine leaflets contained 24% and 20%, respectively. There are several limitations to this study. The Arabic leaflets from only one commercial North American vendor were evaluated and the evaluation included a limited number of drugs. A larger study is necessary to be able to generalize these results.
The study results are consistent with those of previous quality content studies of commercially available English patient drug information leaflets. The results have important implications for patients as access to a reliable source of drug information may prevent harm or limit the suffering from serious adverse drug reactions.
无法获得有用的、科学准确的患者信息是导致药物使用不当的主要原因,这会给患者造成严重伤害,并给医疗系统带来相关成本。1996 年,美国卫生与公众服务部部长将有用的、科学准确的处方药患者信息定义为源自或与美国食品和药物管理局批准的药物专业产品标签一致的信息。先前的质量内容研究发现,美国药店分发的英文患者药物信息传单未能达到定义有用和科学准确信息的最低标准。
根据当前美国食品和药物管理局批准的专业产品标签,为三种已知有严重药物不良反应的药物创建了包含明确要素的评估表,这些要素定义了有用的、科学准确的信息。在当地获得了塞来昔布、帕罗西汀和拉莫三嗪的阿拉伯语患者药物信息传单,并使用与先前在美国进行的质量内容患者药物信息研究中使用的类似方法进行了评估。阿拉伯语传单不符合有用的科学准确信息的定义。塞来昔布传单包含所需信息的 30%,帕罗西汀和拉莫三嗪传单分别包含 24%和 20%。本研究存在一些局限性。仅评估了一家北美商业供应商的阿拉伯语传单,评估也只包括了有限数量的药物。需要进行更大规模的研究才能推广这些结果。
研究结果与先前对商业提供的英文患者药物信息传单的质量内容研究结果一致。这些结果对患者具有重要意义,因为获得可靠的药物信息来源可能会防止严重药物不良反应造成的伤害或减轻其痛苦。